Evidence
Rev Med Suisse. 2023 Apr 26;19(824):807-809. doi: 10.53738/REVMED.2023.19.824.807.
ABSTRACT
Cerebral amyloid angiopathy (CAA) is a common and well-defined small vessel disease characterized by the deposition of amyloid β in the vascular wall. CAA causes devastating outcomes related to intracerebral hemorrhage and cognitive decline in older adults. The shared pathogenic pathway between CAA and Alzheimer’s disease, co-occuring frequently in the same subject, has important implications for cognitive outcomes and novel anti-amyloid-β immunotherapies. In this review, we present the epidemiology, pathophysiology, current diagnostic criteria of CAA, and future developments in the field.
PMID:37133940 | DOI:10.53738/REVMED.2023.19.824.807
Add to Google Keep
Post to X
Share on Linkedin
Estimated reading time: 2 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Cerebral amyloid angiopathy-related cognitive decline: small vessels, big problems
🌐 90 Days
VR Related Evidence Matrix
Evidence Blueprint
Cerebral amyloid angiopathy-related cognitive decline: small vessels, big problems
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Cerebral amyloid angiopathy-related cognitive decline: small vessels, big problems
🌐 365 Days
VR Related Evidence Matrix
